March 27, 2012Open Access

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

AYAnas YounesUniversité Claude Bernard Lyon 1 AGAjay K. GopalCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa SSScott E. SmithThe University of Texas Southwestern Medical Center

Key Points

Key points are not available for this paper at this time.

Abstract

The ADC brentuximab vedotin was associated with manageable toxicity and induced objective responses in 75% of patients with relapsed or refractory HL after auto-SCT. Durable CRs approaching 2 years were observed, supporting study in earlier lines of therapy.

KI fragen

Bookmark

View Full Paper

Cite This Study

Younes et al. (Tue,) studied this question.

synapsesocial.com/papers/69d8240805ee2ba81dbef274 https://doi.org/https://doi.org/10.1200/jco.2011.38.0410

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

KI fragen

Bookmark

View Full Paper